Related Experiment Videos
Hypersensitivity and cross-reactivity to cisplatin and analogues
A A Shlebak1, P I Clark, J A Green
1Department of Haematology, Glasgow Royal Infirmary, UK.
Cancer Chemotherapy and Pharmacology
|January 1, 1995
Summary
A patient experienced hypersensitivity reactions to carboplatin and cisplatin, common ovarian cancer treatments. These severe platinum-based chemotherapy allergies can limit treatment options for some patients.
Area of Science:
- Oncology
- Clinical Pharmacology
- Immunology
Background:
- Ovarian cancer treatment often involves platinum-based chemotherapy agents like carboplatin and cisplatin.
- Hypersensitivity reactions (HSRs) to these agents are a known clinical challenge.
- Previous allergies to unrelated medications (Co-Amoxiclav) or substances (talc) can be noted in patient history.
Observation:
- A 49-year-old woman with relapsing ovarian cancer developed a hypersensitivity reaction (HSR) to carboplatin.
- The patient subsequently experienced an HSR to cisplatin, a related platinum compound.
- The patient had a history of skin rash reactions to Co-Amoxiclav and talc, but no general history of atopy.
Findings:
- The patient's HSRs to both carboplatin and cisplatin highlight potential cross-reactivity or shared allergenic mechanisms within platinum-based drugs.
- Reported cases of severe HSRs to platinum chemotherapy exist in medical literature.
- These reactions can be transient but may be life-threatening in some instances.
Implications:
- Severe platinum-induced HSRs can restrict treatment options for patients with ovarian cancer, germ-cell tumors, and osteogenic sarcoma.
- Alternative treatment strategies may be necessary for patients unable to tolerate standard platinum-based chemotherapy.
- Further research into the mechanisms of platinum hypersensitivity and desensitization protocols is warranted to improve patient outcomes.